Lv4
460 积分 2025-02-19 加入
Nintedanib as the First Treatment for Group of Progressive InterstitialLung Diseases: A Review of Patent Literature
2个月前
已完结
P132 The preferential Pde4b inhibitor nerandomilast (BI 1015550) exhibits antifibrotic and anti-inflammatory effects in human in vitro SSc models
6个月前
已完结
P146 Staying in the flow: PDE4B inhibitor nerandomilast (BI 1015550) improves features of vascular dysfunction in lung fibrosis in vitro and in vivo
6个月前
已完结
Development of a Scalable Asymmetric Process for the Synthesis of Selective PDE4B Inhibitor Nerandomilast (BI 1015550)
6个月前
已完结
Insights Into the Cellular and Molecular Mechanisms Behind the Antifibrotic Effects of Nerandomilast
6个月前
已完结
Targeting Lp-PLA2 inhibits profibrotic monocyte-derived macrophages in silicosis through restoring cardiolipin-mediated mitophagy
6个月前
已完结
A Comprehensive Review on Pulmonary Fibrosis (PF): Histological Spectrum, Diagnosis, Risk Factors, Pathogenesis, Molecular Pathophysiology, and Current Treatment Options
7个月前
已完结
Alveolar fibroblast lineage orchestrates lung inflammation and fibrosis
10个月前
已完结
皖公网安备34019202002308
